castle biosciences, inc. specializes in diagnostic tests for cancers. founded in 2008, the company goal has been to help advance the care for cancers through objective testing. our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. currently, castle biosciences has tests to help doctors treat cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma and glioma. we have active research programs in rectal cancer and soft tissue sarcoma, and anticipate tests for these and other under-served cancers to be available in the near future please visit us at www.castlebiosciences.com for more information on our company and products.
Company profile
Ticker
CSTL
Exchange
Website
CEO
Derek J. Maetzold
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
AltheaDx, Inc. • Cernostics, Inc. • Myriad myPath, LLC • Castle Narnia Way Real Estate Holding 1, LLC ...
IRS number
770701744
CSTL stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
27 Mar 24
S-8
Registration of securities for employees
28 Feb 24
S-3
Shelf registration
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
28 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
S-8
Registration of securities for employees
4 Dec 23
8-K
Departure of Directors or Certain Officers
9 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Castle Biosciences Reports Third Quarter 2023 Results
2 Nov 23
Transcripts
CSTL
Earnings call transcript
2023 Q3
2 Nov 23
CSTL
Earnings call transcript
2023 Q2
2 Aug 23
CSTL
Earnings call transcript
2023 Q1
3 May 23
CSTL
Earnings call transcript
2022 Q4
28 Feb 23
CSTL
Earnings call transcript
2022 Q3
2 Nov 22
CSTL
Earnings call transcript
2022 Q2
12 Aug 22
CSTL
Earnings call transcript
2022 Q1
10 May 22
CSTL
Earnings call transcript
2021 Q4
1 Mar 22
CSTL
Earnings call transcript
2021 Q3
9 Nov 21
CSTL
Earnings call transcript
2021 Q2
11 Aug 21
Latest ownership filings
4
DEREK J MAETZOLD
22 Mar 24
4
DEREK J MAETZOLD
11 Mar 24
144
Notice of proposed sale of securities
7 Mar 24
4
Tobin W Juvenal
6 Mar 24
4
Kristen M Oelschlager
6 Mar 24
4
Frank Stokes
6 Mar 24
4
DEREK J MAETZOLD
6 Mar 24
4
DANIEL BRADBURY
6 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
SC 13G
Granahan Investment Management, LLC
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 91.22 mm | 91.22 mm | 91.22 mm | 91.22 mm | 91.22 mm | 91.22 mm |
Cash burn (monthly) | 1.55 mm | 3.58 mm | 3.21 mm | 7.10 mm | (no burn) | 2.52 mm |
Cash used (since last report) | 9.22 mm | 21.30 mm | 19.12 mm | 42.21 mm | n/a | 14.98 mm |
Cash remaining | 82.00 mm | 69.93 mm | 72.11 mm | 49.01 mm | n/a | 76.24 mm |
Runway (months of cash) | 52.9 | 19.5 | 22.4 | 6.9 | n/a | 30.3 |
Institutional ownership, Q3 2023
92.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 138 |
Opened positions | 22 |
Closed positions | 16 |
Increased positions | 52 |
Reduced positions | 40 |
13F shares | Current |
---|---|
Total value | 376.01 bn |
Total shares | 25.31 mm |
Total puts | 25.30 k |
Total calls | 60.00 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Wasatch Advisors | 2.78 mm | $46.97 bn |
Granahan Investment Management | 2.49 mm | $42.02 bn |
BLK Blackrock | 2.14 mm | $36.08 bn |
PFG Principal Financial Group Inc - Registered Shares | 1.48 mm | $25.03 bn |
Vanguard | 1.44 mm | $24.31 bn |
BLVGF Bellevue | 1.23 mm | $20.74 bn |
Sofinnova HealthQuest Partners | 983.58 k | $52.32 mm |
Deerfield Management | 946.62 k | $15.99 bn |
Bradbury Daniel | 743.42 k | $49.92 mm |
Kornitzer Capital Management | 648.22 k | $10.95 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Mar 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.7 | 12 | 248.40 | 10,455 |
21 Mar 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.7 | 12 | 248.40 | 10,455 |
21 Mar 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.7 | 12 | 248.40 | 10,455 |
21 Mar 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.7 | 11 | 227.70 | 10,457 |
21 Mar 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.7 | 37 | 765.90 | 77,439 |
21 Mar 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.7 | 37 | 765.90 | 88,542 |
21 Mar 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | No | Yes | 20.7 | 73 | 1.51 k | 69,733 |
20 Mar 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.27 | 374 | 7.58 k | 10,467 |
20 Mar 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.27 | 374 | 7.58 k | 10,467 |
20 Mar 24 | Maetzold Derek J | Common Stock | Sell | Dispose S | Yes | Yes | 20.27 | 374 | 7.58 k | 10,467 |
News
Castle Biosciences Gives Long-Term Outcomes Data Shared At SSO 2024 Show That Patients With A Low-Risk DecisionDx-Melanoma Test Result Were Recurrence Free At 3-Years, Including Those Who Utilized The Test To Help Guide the Decision To Avoid An SLNB
22 Mar 24
Castle Biosciences New Study Showing The Drug-Drug Interactions And Lifestyle Factors Provided By ' IDgenetix Test Improve Medication Recommendations Over Drug-Gene Interactions Alone For Patients 65 And Older
15 Mar 24
Castle Biosciences To Present New Data Highlighting The Clinical Value Of Its Dermatologic Tests For Patients With Skin Cancer At The 2024 American Academy Of Dermatology Annual Meeting
8 Mar 24
Keybanc Maintains Overweight on Castle Biosciences, Raises Price Target to $28
1 Mar 24
Scotiabank Maintains Sector Outperform on Castle Biosciences, Raises Price Target to $37
1 Mar 24
Press releases
Castle Biosciences Announces Updates to its Board of Directors
27 Mar 24
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
25 Mar 24
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
22 Mar 24
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences' IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
15 Mar 24
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
12 Mar 24